SPOTLIGHT: Trial participants lose Amgen suit

Eight people who participated in a trial of Amgen's experimental therapy for Parkinson's have lost their suit aimed at forcing the biotech giant to continue providing them with the drug. A federal judge said that Amgen had the right to terminate the drug trial. Story

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.